FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient responses.
A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient responses.
What's Your Reaction?
